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Purpose Mucopolysaccharidoses (MPS) are a group of rare 
lysosomal storage disorders associated with involvement of 
multiple organs along with a generalised skeletal dysplasia. 
Both haematopoetic stem cell transplant and enzyme re-
placement therapy have improved the outlook for patients 
while surgery remains high-risk and there is little information 
on clinical or functional outcome to justify many of the surgi-
cal procedures performed. This paper aims to summarise the 
orthopaedic surgical procedures in MPS patients for which 
quality of life (QoL) and functional data are available and to 
describe additional QoL and functional measurement tools 
of relevance to the assessment of orthopaedic outcomes in 
MPS.
Methods We reviewed the available literature to look for re-
ported outcomes of orthopaedic surgery to lower and upper 
limbs and the spine. In addition, we describe the general and 
MPS-specific health measures that might be of relevance to 
the orthopaedic surgeon. 
Results There is some evidence in the literature that orthopae-
dic surgery may improve QoL and function in some specific 
aspects of the MPS condition (in relation to genu valgum, 
carpal tunnel syndrome and trigger digits); however, the lit-
erature is sparse and consists of level 4/5 studies only. Further 
studies of these conditions should include QoL and function-
al assessment in order to confirm or refute these reports. In 
other areas (spine and hip), outcomes are judged largely on 
radiographic appearances with little clinical correlation and 
short follow-up; however, one long-term study of function 
following hip dysplasia surgery suggests poor outcomes. 
Anaesthetic morbidity/mortality is not insignificant in these 
complex patients with multi-organ involvement. Careful 
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 assessment is required, particularly when there is neurologi-
cal involvement. 
Conclusions Orthopaedic surgeons involved with MPS pa-
tients should be encouraged to use and report measures of 
QoL and function with respect to musculoskeletal manifes-
tations and response to surgery, recognising that such as-
sessments in these complex and challenging patients may 
require a multidisciplinary approach.
Cite this article: Williams N, Challoumas D, Eastwood DM. 
Does orthopaedic surgery improve quality of life and func-
tion in patients with mucopolysaccharidoses? J Child  Orthop 
2017;11:289-297. DOI 10.1302/1863-2548.11.170042
Keywords: Mucopolysaccharidosis; quality of life; function; 
orthopaedic surgery
Introduction
Mucopolysaccharidoses (MPS) are a group of disorders 
caused by single enzyme defects resulting in abnormal 
glycosaminoglycan (GAG) metabolism with multisystem 
effects. Symptoms often manifest in infancy or early child-
hood. Eleven distinct enzyme deficiencies cause seven rec-
ognised MPS syndromes.1
All MPS disorders involve the musculoskeletal system. 
Dysostosis multiplex refers to a characteristic constella-
tion of radiographic anomalies (Table 1) that is prominent 
and progressive in MPS. The underlying pathophysiology 
is not well-understood and histological findings2 likely 
reflect complex secondary alterations in cell-signalling 
rather than direct effects of GAG deposition. 
The outlook for patients with many MPS subtypes has 
significantly improved due to haematopoetic stem cell 
transplant (HSCT) for rapidly progressive MPS I (Hurler) 
patients and enzyme replacement therapy (ERT) for MPS 
I, II, IV and VI.3 Unfortunately, these treatments fail to 
halt the progression of certain systemic manifestations, 
including musculoskeletal abnormalities. This leads to an 
increasing number of ageing patients with partially cor-
rected abnormalities4 and orthopaedic surgery is proba-
bly increasing in the MPS population.5 
Surgery in MPS remains high-risk4,6 and must be justi-
fied on clinical grounds. Measures of quality of life (QoL) 
and function are important to determine the clinical inter-
play in this complex multisystem disease,3 yet reported 
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outcomes for orthopaedic surgery in MPS more com-
monly focus on radiological and other musculoskeletal 
specific measures, rather than evaluating the patient’s 
overall response to orthopaedic intervention. 
The aims of this paper are:
1. to summarise the orthopaedic surgical procedures in 
MPS patients for which QoL and functional data are 
available; and  
2. to describe additional QoL and functional measurement 
tools of relevance to the assessment of orthopaedic 
outcomes in MPS. 
QoL and function following orthopaedic 
surgery in MPS patients: lower limb
Genu valgum
Surgery for genu valgum is usually performed in MPS IV 
(highest incidence), I, II and VI.7-9 Interventions include 
guided growth techniques, osteotomies, gradual cor-
rection with the use of external fixation and total knee 
arthroplasty for end-stage deformities.2,10 If using guid-
ed-growth techniques, surgery should be offered early as 
MPS patients have reduced peak growth velocity.2 
23 MPS IVA patients underwent distal femoral and/
or proximal tibial eight-plate hemi-epiphysiodesis at a 
mean age of 8.3 years (4 to 15) with average follow-up 
of 44 months (19 to 84).9 Three patients underwent 
repeat hemi-epiphysiodesis and one femoral osteotomy 
was performed for residual deformity. Functional out-
comes were assessed subjectively according to the use 
of mobility aids and objectively using the 6-minute walk 
test (6MWT). Of the 23 patients, 19 remained mobile at 
final follow-up; three previously mobile patients became 
immobile post-surgery for no obvious medical reason: 
one post osteotomy, one a few months after eight-plate 
insertion and one three years after eight plate insertion. 
The 6MWT is a submaximal intensity endurance test 
assessing cardiorespiratory and musculoskeletal function 
in the MPS population.11,12 It has been used extensively in 
MPS clinical research to characterise natural history,11,13 as 
well as a primary measure of efficacy in trials of ERT.14-18 
The test is performed on a 30-m long, flat course and the 
patient is instructed to walk as far as possible in 6 min-
utes, using any of their normal walking aids.12 In research 
settings, the test is often performed on two separate days, 
with either the average result taken for analysis15,16,19 or the 
greater distance.14 Upper and lower limits for inclusion are 
generally set to minimise any ceiling effect and to exclude 
patients whose walking has deteriorated to a point where 
it is irrecoverable despite therapy.11,15 Correction of genu 
valgum in MPS by hemi-epiphysiodesis was associated 
with an average improvement of 69.5 m walking distance 
(30% improvement) post-surgery (p = 0.03) in the 15/23 
patients for whom 6MWT data were available.9 However, 
patients remain significantly impaired. The post-surgery 
average distance covered of 297 m contrasts strongly with 
a distance of 618 ± 79 m seen in healthy individuals aged 
5 to 17 years.20 
Hip dysplasia
Hip dysplasia is found in almost all MPS I patients and also 
in MPS II, III, IV and VI. As in other childhood conditions 
of hip subluxation and dislocation, acetabular and femo-
ral osteotomies have been performed to achieve femoral 
head coverage.2,21 Hip development in these patients is 
associated with femoral head epiphyseal dysplasia that is 
osteonecrosis-like but not related to surgical intervention. 
In MPS III, the changes are less frequent but more often 
resemble true osteonecrosis.2,10,22 High rates of recurrent 
hip subluxation post-operatively have also been reported 
for MPS IV.23 Total hip replacement may become more 
common with systemic MPS therapy leading to prolonged 
lifespan.2 A 2013 consensus statement recommended 
consideration of early surgical hip reconstruction in MPS 
I patients following HSCT, but there was not consensus 
as to whether surgery should be offered to all patients to 
prevent complications or only symptomatic patients.24 
The only study reporting functional outcomes following 
hip surgery in MPS does not support early hip reconstruc-
tion in MPS I post-HSCT if the goals are satisfactory long-
term radiological and functional outcomes.25 A total of 13 
patients (24 hips) underwent surgery, with the majority 
undergoing a Salter pelvic osteotomy +/- proximal femo-
ral osteotomy, a single patient undergoing femoral oste-
otomies only and another open reduction in conjunction 
with femoral and pelvic osteotomies. The average age at 
surgery was four years (2 to 6.3) and average follow-up 
was 14.6 years (10.3 to 21.6). Despite achieving stable, 
well-covered hips, at final follow-up advanced degener-
ative changes were seen radiologically in 10/24 (41%) 
hips. The authors used the Harris Hip Score (HHS)26 for 
assessment of function. The score has a maximum of 100 
points (best possible outcome) and cases with scores less 
than 70 are consistent with poor hip function and can 
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be considered surgical failures.27 Of 13 cases, seven were 
considered surgical failures in this series. There may be a 
role for hip reconstruction in terms of improving anatomy 
for a later total hip arthroplasty but this would be specu-
lative and not measurable in terms of QoL or functional 
outcome measures.
Further evidence that radiological hip pathology in 
MPS has poor correlation with function was provided by 
an assessment of pelvic radiographs reported in the previ-
ously described MPS IV genu valgum study.9 There was no 
correlation between 6MWT distances and degree of hip 
migration, and patients with hip migration percentage 
greater than 40% had no increased probability of being 
wheelchair-bound. 
Ankle and foot deformity
Ankle valgus and foot deformities of equinus, hindfoot 
valgus and forefoot adductus with prominence of the first 
metatarsal head and curly toes are seen in MPS.28 Non-sur-
gical interventions include orthotics and custom footwear 
and surgical interventions include guided-growth tech-
niques and osteotomies.2,29 Surgical functional and QoL 
outcomes have not been reported for foot and ankle pro-
cedures in MPS. 18 patients, with a mean age of 10.3 years 
(4 to 21), with MPS I treated with HSCT who had not under-
gone foot and ankle surgery were evaluated for baseline 
function using the Oxford Foot and Ankle Questionnaire 
for Children (OxAFQ-C). The OxAFQ-C is a 15-item child- 
or parent (proxy)-reported health status questionnaire 
validated for children aged five to 16 years.30 Questions 
cover physical, school and play, and emotional domains, 
with an additional question regarding footwear. A score of 
60 is considered healthy.28 Four of 18 patients tested with 
MPS I had a score of 60. The average score was 45.7 (11 
to 60). The functional domains scored lower than those 
associated with emotional impact or school and play. Ten 
of 18 patients were unable to wear stock footwear.
Upper limb
Skeletal deformities
Upper extremity skeletal deformities are most severe in 
MPS IV due to the associated joint laxity. Severe ulnar devi-
ation at the wrist can be treated with external splints or 
surgically with wrist arthrodesis or partial arthrodesis.8,31 
Function and QoL outcomes following wrist arthrodesis 
have not been reported in MPS.
Carpal tunnel syndrome and trigger fingers 
Carpal tunnel syndrome is essentially unknown in chil-
dren generally but common in MPS I, II and VI.32 Many 
MPS children have no obvious symptoms33 and routine 
neurophysiological testing from five years of age has been 
recommended to permit early open carpal tunnel release 
before permanent nerve damage occurs. Concomitant 
neurolysis of the median nerve is controversial.34,35
Trigger fingers are seen frequently (MPS I, II and VI) and 
often present in association with carpal tunnel syndrome 
(especially types I and II).36 Trigger digits are treated sur-
gically with an A1 and/or A3 pulley release. One paper 
recommends partial resection of the flexor digitorum 
superficialis tendon and careful debridement of the teno-
synovial deposits37 to reduce recurrence. 
17 children who underwent open carpal tunnel sur-
gery with or without concomitant trigger digit release 
were evaluated for post-operative hand function using 
a questionnaire, the details of which were not reported 
but included asking parents to grade the post-operative 
hand function improvement; the frequency of hand pain, 
numbness, and night pain; and their child’s difficulty per-
forming tasks.37 The average length of the post-operative 
follow-up period was three years. Of the eight children 
who underwent carpal tunnel surgery as well as trig-
ger digit surgery (A1 +/- A3 pulley release +/- resection 
of flexor digitorum superficialis slip), the parents of four 
patients reported no difficulty with tasks, two reported 
occasional difficulties and two reported frequent difficul-
ties. Parents reported increased dexterity and spontaneous 
hand use. The authors caution that for optimal outcomes, 
trigger digits must be distinguished pre-operatively from 
joint stiffness. Phalangeal joint contracture is found in all 
MPS types, except for MPS IV (and IX).36 
Spine
Thoracolumbar and cervicothoracic deformity
Thoracolumbar kyphosis is a classic finding in MPS I and 
has also been reported in MPS II,38 IV and VI.10,39-41 Scoliosis 
can occur in association with kyphosis or in isolation, but 
surgery for scoliosis is uncommon in the absence of signif-
icant kyphosis. 10,42,43 
Cervicothoracic kyphosis can also occur in MPS I 
and  IV, particularly in conjunction with thoracolumbar 
kyphosis.42,44
Deformity progression,40,43 defined as > 10° increase 
over a 12-month period,41,45 kyphosis > 40° to 45°,39,41,45 
disruption of sagittal balance41 and/or neurological 
 compromise39 are reported indications for surgical inter-
vention.
There are no studies reporting QoL and function 
before  and after spinal surgery for thoracolumbar 
kyphosis. In fact, it has been suggested that QoL is not 
 significantly compromised, even in the presence of severe 
spinal deformity46, and, in the absence of symptoms, 
some  surgeons advocate surgery only for progressive 
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kyphosis > 70°.2 Although it can be assumed that neu-
rological compromise resulting from thoracolumbar 
kyphosis would significantly affect QoL and function, neu-
rological compromise as an indication for surgery in this 
circumstance has been reported rarely.47 Thoracolumbar 
spine surgery has been ineffective in the medium term in 
preventing neurological deterioration in patients where 
the deterioration has been attributed to pathology else-
where in the spinal column, ischaemic insult or ongoing 
deposition of GAG breakdown products.42,48 
Craniocervical and upper cervical spine pathology
Upper cervical and craniocervical spine pathology is 
 commonly seen in MPS IV and VI and less commonly in 
MPS I.10 Myelopathy and neurological abnormalities are 
more commonly associated with pathology at this level 
than at the thoracolumbar region. 
While surgery is recommended to prevent devastating 
neurological compromise, there are no studies of QoL 
or function following cervical spine surgery in MPS to 
demonstrate surgical benefit. In fact, reports of neurologi-
cal function and mobility following upper cervical surgery 
in MPS suggest that the usual outcome is stabilisation 
of neurological function rather than improvement.49-51 
This contrasts with the few reported cases of neurologi-
cal compromise associated with thoracolumbar surgery, 
where symptoms improved post-surgery.52 Expectations 
for patients presenting with established neurological 
compromise should be managed appropriately in the 
light of these reports. 
Additional QoL and functional 
measurement tools in MPS
The following disease-specific or generic QoL and func-
tional assessment tools (Table 2) have been used in the 
setting of clinical management and/or research involving 
MPS patients and may be useful for the orthopaedic sur-
geon involved in MPS care. 
The MPS-Physical Performance Measure (MPS-PPM) 
was developed specifically for MPS I.53 A revised version 
was used on ten MPS I children confirming its utility in 
identifying limitation in age-related physical perfor-
mance. Good inter-rater and test-retest reliabilities were 
reported.54
The MPS Health Assessment Questionnaire (MPS-HAQ) 
is disease-specific but not type-specific, measuring disabil-
ity in patients aged over eight years.55 Parini et al56 com-
pared MPS-HAQ scores at baseline and at end of ERT (five 
to nine years), and showed that the subgroup of MPS IIA 
patients (CNS involvement) improved in 9/52 but wors-
ened in 32/52 items, while MPS IIB patients (no CNS 
involvement) improved in 23/52 items and worsened in 
only 3/52. 
The Hunter Syndrome-Functional Outcomes for Clin-
ical Understanding Scale (HS-FOCUS) is type-specific, 
assessing impact of MPS II on function.57 Raluy-Calado et 
al58 evaluated MPS II patients with the HS-FOCUS ques-
tionnaire and other generic tools: 1) Childhood Health 
Assessment Questionnaire (CHAQ); 2) Childhood Health 
Questionnaire (CHQ); and 3) Health Utilities Index-3 
Table 2. Measurement tools used in the general assessment of mucopolysaccharidoses (MPS) patients.





I 7 arm function tests
4 leg function tests 
2 endurance tests
MPS-PPM (Modified) (Haley) I 8 timed functional tests 
2 endurance tests
MPS-HAQ
MPS Health Assessment 
Questionnaire
All 52-item questionnaire > 8 years Caregivers
HS Focus 
Hunter Syndrome-Functional 
Outcomes for Clinical 
Understanding Scale
II 6 functional domains







Childhood Health Assessment 
Questionnaire
8 domains (30 items) 
•	 Functional capacity 





•	 Physical and 
•	 Psychosocial health status
Patient version 





•	 describe patient experience of therapy 
•	  the long-term outcomes of disease or therapy
•	 the efficacy of health care interventions 
•	 the health status of general populations
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(HUI 3). Children with MPS II were most compromised in 
physical function and the activities of daily living (ADL), 
along with a considerable psychological impact, affecting 
self-esteem and family cohesion most notably.
The CHQ was used to describe QoL in patients with the 
attenuated form of MPS II and its change over time. Physi-
cal QoL decreased while psychosocial QoL increased with 
age, although older children reported an increasing sense 
of inadequacy and low self-esteem.59 
Other generic instruments used in MPS patients 
include the Pediatric Quality of Life Inventory (Peds-QL), 
KIDSCREEN, European QoL-5 Dimensions (EuroQoL; 
adults only) and Short Form questionnaire 36 (SF-36; 
adults only).60-62
The Paediatric Outcomes Data Collection Instrument 
(PODCI) (www.aaos.org/outcomes) has become the tool 
of choice for assessing musculoskeletal-related function 
and QoL in many conditions, including MPS63,64 (Table 3). 
As well as assessing baseline status, it is used for assessing 
medical and surgical interventions with good reliability, 
construct validity and sensitivity to change.63
O’Brien et al65 used the PODCI tool in 25 MPS patients 
of four different types and demonstrated compromised 
musculoskeletal function in patients compared with nor-
mally developing children in most domains. The lowest 
scores were recorded in the sports/physical condition-
ing scale and the highest in the happiness scale. Overall, 
MPS VI had the highest scores and MPS II the lowest, with 
significantly more severe deficits in upper extremity and 
physical function compared with other subtypes. 
White et al63 also used the PODCI to assess the benefits 
of ERT on function and QoL in seven MPS II children. All 
patients displayed limitations in shoulder range of motion 
(ROM) and a combination of compromised function in 
other joints, including the hip, knee, elbow and ankle 
with spinal deformity in some. Five of the seven patients 
received ERT and serial PODCI exams were performed 
(at baseline and one to two years’ follow-up) to detect 
changes in function. Positive trends towards improvement 
were seen in all domains but statistical significance was 
reached in only three (‘transfers and basic mobility’, ‘sports 
and physical functioning’ and ‘global functioning’). 
For the specific subjective assessment of hand function, 
Aslam et al31 (Table 4) described a questionnaire based on 
the principles of the World Health Organization Interna-
tional Classification of Functioning, Disability and Health 
(WHO ICF) which provides a holistic approach based 
on four domains. Of the ten MPS IV patients studied, all 
reported hand/upper limb weakness, while pain, paraes-
thesia and stiffness were variable. Seven and ten out of 
ten children felt moderately limited in normal classroom 
activities and physical education/sports, respectively. All 
patients felt supported by their family and healthcare 
team. The most difficult activities were carrying heavy 
objects, personal hygiene, pouring liquids and making 
the bed, while using games consoles was not difficult. 
Only 17% (aged < 10 years) and 9% (aged > 10 years) of 
responses were scored ‘no activity limitation’.31 
Other recommended questionnaires for assessing 
upper limb function include the Functional Dexterity Test 
(FDT) and Disabilities of Arm, Shoulder and Hand (DASH);8 
however, no studies utilising these tools in MPS have been 
identified.
Gross and fine motor skills contribute significantly to 
motor functioning. Tools that have been used to assess 
these skills in MPS populations include the Vineland Adap-
tive Behavioral Scales (VABS), Peabody Developmental 
Motor Scales edition two (PDMS2) and Denver Develop-
mental Screening Test (DDST).5
Objective measures
A number of clinical tests assessing musculoskeletal func-
tion in MPS patients have been described. Raluy-Calado 
et al58 used objective clinical measures in addition to the 
four questionnaires described to assess their validity. One 
measure was joint range of motion (JROM): the authors 
assessed a total of 23 motions for the shoulder, elbow, 
wrist, index finger, hip and ankle bilaterally and calculated 
the average value of two measurements at two separate 
visits to determine a global JROM score. Parini et al56 used 
the JROM to quantify musculoskeletal improvement after 
ERT in 13 MPS II patients and reported some increase in 
ROM of shoulders, elbows, hips and knees in the first two 
years of ERT but with no overall statistical significance. 
Aslam et al’s31 objective hand function assessment com-
pared passive and active ROM of the wrist and hand joints 
and looked at grip strength. Large differences between 
passive and active ROMs were interpreted as represent-
ing significant compromise in joint function. In the ten 
Table 3. The Paediatric Outcomes Data Collection Instrument (PODCI).
Age groups Child (age 2 to 10 yrs) Parent administered 
Adolescent (age 11-18 yrs) Parent or child  
administered 
Domains Upper extremity
Transfers and basic mobility
Sports and physical functioning 
Comfort/pain 
Happiness with physical condition
Global functioning
 
Table 4. Aslam hand assessment tool.
Age 
groups
Child (age 2 to 4 yrs)
Child (age 5 to 9 yrs) 
Parent administered 
Adolescent (age > 10 yrs) Parent or child administered 
Domains Body structures
Body functions 
Participation and activities 
Environment 
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patients assessed, the difference in interphalangeal joint 
(IPJt) movement was not clinically significant but active 
movement at the wrist was significantly compromised. 
Both gross grip strength and lateral key grip were severely 
compromised (57% and 93% below the mean normative 
values, respectively).31 
Harmatz et al19 assessed the effects of 48 weeks of 
ERT on endurance, mobility and joint function in MPS VI 
patients and reported significant improvements in all out-
come measures. Endurance and mobility were assessed by 
a 12-minute walk test, a 3-minute stair climb test and the 
Expanded Timed Get-Up-and-Go (ETGG) test (Table 5). For 
joint function assessment, objective measures consisted of 
shoulder ROM, grip and pinch strength, while pain and 
stiffness were assessed by an analogue scale based on the 
Health Assessment Questionnaire (HAQ) and the CHAQ. 
Conclusions
Following improvements in lifespan for MPS patients due 
to developments in HSCT and ERT, orthopaedic surgery in 
MPS is now performed more frequently in certain centres, 
often following guidelines and practices developed for 
patients without MPS.25 A pitfall with this approach is that 
the orthopaedic pathology in MPS is not similar enough 
to other pathologies to ensure satisfactory outcomes in 
MPS patients. The complex pathology may explain poor 
clinical outcomes following reconstructive hip surgery in 
MPS, despite satisfactory initial radiological outcomes.25 
Another problem is the multisystem nature of MPS. 
Cognitive, cardiorespiratory and other musculoskeletal 
disease can all impact on the outcomes following ortho-
paedic surgery. Improvement post-operatively of a specific 
orthopaedic measure may be clinically irrelevant if disease 
elsewhere significantly limits function and QoL. For this 
reason, using general, rather than joint specific functional 
and QoL tools may be more useful in this population. 
Despite advances in medical management, peri-opera-
tive mortality in MPS remains high (4.2% 30-day mortality 
for MPS I)66 Cardiorespiratory complications, including 
airway difficulties account for 63% of deaths. International 
management guidelines for MPS I recommend avoid-
ance of operations requiring general anaesthesia where 
possible and highlight the challenges of providing safe 
peri-operative care in the MPS population.67 MPS types 
with frequent skeletal involvement, are those more likely 
to require orthopaedic surgery but also those with the 
highest anaesthetic risk.10,68,69 Peri-operative spinal cord 
injury in MPS patients is an increasingly recognised com-
plication. This has been reported following both spinal 
and lower limb surgery in patients with MPS I and IV.48,70,71 
In light of these reports, the routine use of spinal cord 
monitoring for all MPS patients undergoing prolonged 
orthopaedic procedures should be considered.72 These 
reports caution against the use of epidural anaesthesia 
in MPS patients as it masks the recognition and potential 
treatment of evolving spinal cord injury. The decision to 
undertake any orthopaedic surgery in an MPS patient 
must be well-considered and should be conducted within 
the context of multidisciplinary management in a centre 
with appropriate experience and expertise. 
There is evidence that orthopaedic surgery may 
improve QoL and function in MPS with genu valgum,9 
carpal tunnel syndrome and trigger digits;37 however, the 
literature is sparse and further studies of these conditions 
should include QoL and functional assessments in order 
to confirm or refute these reports. In contrast, there is evi-
dence that orthopaedic surgery fails to improve QoL and 
function in MPS patients with hip dysplasia, despite suc-
cessful early radiological outcomes.25 
Orthopaedic surgeons involved with MPS patients 
should be encouraged to use and report measures of QoL 
and function with respect to musculoskeletal manifesta-
tions and response to surgery.
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